Details for Patent: 8,207,215

Which drugs does patent 8,207,215 protect, and when does it expire?

Patent 8,207,215 protects ACULAR LS and is included in one NDA.

Protection for ACULAR LS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has five patent family members in three countries.

Summary for Patent: 8,207,215

Patent landscape, scope, and claims:

Title:	Ketorolac tromethamine compositions for treating or preventing ocular pain
Abstract:	Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
Inventor(s):	Muller; Christopher A. (Foothill Ranch, CA), Cheetham; Janet K. (Laguna Niguel, CA), Kuan; Teresa H. (Placentia, CA), Power; David F. (Trabuco Canyon, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	11/842,915
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,207,215
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,207,215

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	ACULAR LS	ketorolac tromethamine	SOLUTION/DROPS;OPHTHALMIC	021528-001	May 30, 2003	AT	RX	Yes	Yes					Y

International Family Members for US Patent 8,207,215

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2468664
Canada	2967362
European Patent Office	3217937
European Patent Office	3777808
World Intellectual Property Organization (WIPO)	2016077726